Report #2863573

Received Oct 7, 2025

A note on interpretation. VAERS reports are unverified and may be incomplete or coincidental. A report does not establish that a vaccine caused an event, and counts should not be used to calculate incidence or infer causation. Full disclaimer

Overview

Sex: Female
Age: Age unknown
State: NY
Recovered: Unknown
Vaccinated: Sep 23, 2025
Onset: Sep 23, 2025
Days to onset: 0
Hospital days: —

Vaccines (1)

Type	Name	Manufacturer	Dose	Lot	Route / Site
MMR	MEASLES + MUMPS + RUBELLA (PRIORIX)	GLAXOSMITHKLINE BIOLOGICALS	UNK	522A7	IM

Symptoms (1)

Incorrect route of product administration

Symptom narrative

intramuscular administration of Priorix; This non-serious case was reported by a pharmacist via call center representative and described the occurrence of subcutaneous injection formulation administered by other route in a female patient who received MMR (Priorix) (batch number 522A7, expiry date 01-MAY-2027) for prophylaxis. On 23-SEP-2025, the patient received Priorix (intramuscular). On 23-SEP-2025, an unknown time after receiving Priorix, the patient experienced subcutaneous injection formulation administered by other route (Verbatim: intramuscular administration of Priorix). The outcome of the subcutaneous injection formulation administered by other route was not applicable. This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences.